FINWIRES · TerminalLIVE
FINWIRES

欧州株は米国市場で取引され、米国預託証券(ADR)は木曜日の取引で上昇した。

By

-- 木曜午前遅く、米国預託証券(ADR)が上昇したことを受け、欧州株は米国市場で取引され、S&Pヨーロッパ・セレクトADR指数は2.20%高の1,818.51となった。 欧州大陸では、製薬会社のノボ・ノルディスク(NVO)と銀行のINGグループ(ING)がそれぞれ5.3%と4.9%上昇し、上昇を牽引した。これに続き、バイオ医薬品会社のグリフォルス(GRFS)と消費財会社のユニリーバ(UL)がそれぞれ3.2%と3.1%上昇した。 欧州大陸では、インターネット広告会社のクリテオ(CRTO)と通信会社のノキア(NOK)がそれぞれ3.2%と1.9%下落し、下落を牽引した。 英国では、クルーズ船運航会社のカーニバル(CUK)と公益事業会社のナショナル・グリッド(NGG)がそれぞれ4.8%と3.5%上昇し、上昇を牽引した。続いて、ロイズ・バンキング・グループ(LYG)と通信事業者ボーダフォン・グループ(VOD)がそれぞれ2.6%と2.3%上昇した。 英国とアイルランドの下落銘柄では、ソフトウェア企業のエンダバ(DAVA)とバイシクル・セラピューティクス(BCYC)がそれぞれ5.2%と2.3%下落した。これに続き、バイオ医薬品企業のアマリン(AMRN)とメレオ・バイオファーマ・グループ(MREO)がそれぞれ1.3%と0.9%下落した。

Related Articles

Research

Research Alert: The Clorox Company Beats Estimates Driven By Household And International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CLX reported Q3 FY 26 net sales of $1.67B, flat Y/Y with organic sales down 1%, while adj. EPS of $1.64 grew 13% and beat consensus by $0.10. Gross margin contracted 140 bps to 43.2% due to elevated manufacturing costs and unfavorable mix, though disciplined expense management supported earnings. Mixed segment performance showed Household and International delivering growth of 3% and 8%, respectively, while Lifestyle declined 9% on lower consumption and inventory adjustments. Management updated FY 26 guidance expecting net sales to decline ~6% with organic sales down ~9%, including a 7.5%-pt ERP headwind. Adj. EPS guidance of $5.45-$5.65 represents a 27%-29% decline, with gross margin expected to contract 250-300 bps from GOJO inventory step-up and elevated energy costs. The April 1 GOJO acquisition expands the health portfolio though near-term integration costs pressure results. We believe the completed $580M digital transformation positions CLX for long-term operational improvements despite macro headwinds.

$CLX
Research

Research Alert: Rivn: Q1 Eps Ahead Of Consensus; 2026 Guidance Unchanged

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Rivian (RIVN) posted Q1 adjusted EPS of -$0.55 vs. -$0.41, ahead of the -$0.60 consensus. Revenue rose 11% to $1.38B ($10M ahead of consensus) on a 20% increase in total vehicle sales to 10,365 units, augmented by a 49% Y/Y increase in software and services revenue to $473M. RIVN's gross margin contracted 800 bps to 8.6%, but was ahead of the 8.4% consensus. The quarter's financial results reflect the company's strategic pivot toward broader market accessibility with the R2, though at the cost of near-term profitability. RIVN maintained prior 2026 guidance for adjusted EBITDA, vehicle deliveries, and capex. The company ended Q1 with cash of $4.8B, down from $6.1B at year-end 2025. Shares are trading 1% higher in after-hours trading. RIVN's Q1 earnings were ahead of expectations, although cash burn remains a key concern, with free cash flow deteriorating, driven by increased operating expenses and working capital consumption. Execution risks remain high given challenging demand facing the broader EV industry.

$RiVN
Australia

Tanger Q1 Core FFO, Revenue Rise; 2026 Guidance Increased

Tanger (SKT) reported Q1 core funds from operations late Thursday of $0.59 per diluted share, up from $0.53 a year earlier.Analysts polled by FactSet expected $0.58.Revenue in the three months ended March 31 rose to $150.4 million from $135.4 million a year earlier.Analysts surveyed by FactSet expected $142.9 million.The company raised 2026 FFO guidance to $2.42 to $2.50 per diluted share from $2.41 to $2.49.Analysts polled by FactSet expect $2.47.Tanger shares fell 2.3% in after-hours trading.

$SKT